Full-Time
Logistics Analyst
Azenta
1,001-5,000 employees
Automated cold-chain sample management and multiomics
No salary listed
Wotton-under-Edge, UK
In Person
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Azenta
See people who can refer or advise you
- A bachelor's degree in Business, Supply Chain, Logistics, or a related field is required.
- Proven experience with international logistics is required.
- Experience with cold chain logistics and arranging biological sample shipments is required.
- Understanding of hazardous materials and dangerous goods shipping requirements is required.
- Experience working with Oracle Cloud is required.
- Experience working with Freight Payment Centers is required.
- General knowledge of transport tariffs is required.
- Strong systems aptitude and working knowledge of global transportation carriers and services are required.
- A strong understanding of incoterms is required.
- Excellent troubleshooting and problem-solving abilities are required.
- High proficiency in Microsoft Excel and the ability to analyze data and use findings to make improvements are required.
- Analyze ocean, air, domestic, and international freight contracts and shipping routes to assist with contract negotiations.
- Implement freight payment services for international locations.
- Request freight quotes from approved carriers and prepare and evaluate rates and proposals competitively.
- Maintain contract rates and tariffs, including applicable surcharges.
- Prepare and update rate summaries in Microsoft Excel.
- Review and evaluate freight invoices for accuracy.
- Coordinate with internal cross-functional teams, vendors, freight forwarders, and carriers to ensure inbound and outbound shipments are booked and shipped on time and cost-effectively across the carrier base.
- Provide internal customer support to Compliance, Supply Chain, Global Operations, and Finance for daily tracking, expedited shipments, product freight cost analysis, and invoice approval.
- Monitor logistics volume and spending and identify cost-saving opportunities.
- Ensure that freight invoice general ledger coding is accurate.
- Collaborate routinely with freight forwarders and carriers to address performance issues, resolve problems, and file damage claims.
- Understanding of biological sample permitting is preferred.
Azenta provides end-to-end life sciences solutions focused on sample management and genomic services. Its SMS segment offers automated ultra-cold storage, cryogenics, consumables, instruments, and repository services, while the Multiomics segment (GENEWIZ) provides genomic services like sequencing and gene synthesis. The company integrates hardware, consumables, software, and biorepository capabilities to collect, store, and analyze samples across pharma, biotech, academia, and healthcare, with about 55% recurring revenue. Its goal is to speed up drug development, clinical research, and advanced cell therapies by maintaining sample integrity from collection to data analysis.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
1978
Get referred to Azenta
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 4, 2026 revenue rose 12% to $161 million; guidance reached $613-$618 million.
- Azenta completed a $50 million buyback and still held $200 million authorization on June 30, 2026.
- B Medical Systems closed July 1, 2026, sharpening focus on core life-sciences businesses.
What critics are saying
- May 5, 2026 goodwill impairment exposed Multiomics weakness and triggered securities investigations.
- Automated Stores rework and North America order softness keep margins and bookings volatile through 2026.
- If Multiomics keeps missing, Azenta's 2029 plan slips again and acquisitions lose strategic logic.
What makes Azenta unique
- Azenta owns recurring biorepositories, consumables, and multiomics, reducing pure project dependence.
- UK Biocentre, acquired March 4, 2026, deepens Europe sample-storage density and automation reach.
- Its 4titude PCR and custom manufacturing serve diagnostic-kit workflows with ISO 13485 quality.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
Azenta Life Sciences' custom PCR solutions for diagnostic kit manufacturers. Published: 18 August 2026 Expanding on its 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation for partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows As molecular diagnostics drive advances in healthcare, manufacturers are under mounting pressure to provide high-quality, scalable diagnostic kits while meeting stringent requirements. Not all applications are soluble using off-the-shelf solutions. Azenta Life Sciences offers customised molecular diagnostic solutions to support these evolving needs. The solutions combine proven PCR consumables with bespoke design and manufacturing expertise. Whether adapting existing products or creating custom solutions, the company provides flexible options across PCR plates, sealing materials, sample tracking, and automation-compatible consumables to help customers enhance reproducibility, simplify manufacturing, and accelerate product development. Baskar Anand, global product manager, Azenta, said, "Its customisation capabilities extend from concept through to production. Customers can specify plate formats, frame and well colours, coatings, surface treatments, seal materials, printing, chemical compatibility, and barcode or 2D coding options, alongside contract manufacturing to create solutions that exactly fit your application. "Our customers need more than a catalogue of consumables - they need solutions designed around their manufacturing processes. By combining high-quality products with flexible customisation, we're helping diagnostic kit manufacturers build workflows that are efficient, reproducible, and ready to scale." Azenta works with manufacturers to develop customised solutions for applications such as infectious disease diagnostics, supporting automated reagent dispensing, secure heat sealing, sample traceability, and compatibility with downstream analytical platforms. Azenta manufactures custom products in ISO 9001- and ISO 13485-certified facilities, providing the quality systems, consistency, and supply reliability that a diagnostic kit manufacturer requires.
Azenta exceeded Wall Street expectations in its second quarter, posting revenue of $161.2 million against estimates of $149.2 million and adjusted earnings per share of $0.16 versus the anticipated $0.10. The company reported 12% year-on-year revenue growth. CEO John Marotta attributed the outperformance to robust growth in biorepositories and consumables segments, alongside improved execution in Multiomics, particularly in Europe and China. Adjusted EBITDA reached $18.46 million, beating analyst estimates of $16.4 million. During the earnings call, analysts focused on sustainability of the North American recovery, order trends, and capital equipment conversion. Marotta noted strong growth in China and Europe but highlighted ongoing challenges in North America's capital equipment market. The company is transitioning from customised to configurable systems whilst maintaining a disciplined approach to capital allocation and mergers and acquisitions.
Azenta reported third-quarter revenue of $161.18 million, up from $143.86 million year-over-year, and swung to a quarterly net income of $2.46 million from a net loss. The company raised full-year revenue guidance to $613–$618 million and completed a $50 million share buyback of 2.3 million shares. Despite the quarterly improvement, Azenta still reported a net loss of $173.77 million over the first nine months of fiscal 2026, higher than the previous year. The combination of improving quarterly profitability and the sizeable buyback signals management's focus on operational improvement and disciplined capital allocation. The narrative projects $685 million revenue and $37.8 million earnings by 2029, requiring 4.7% yearly revenue growth.
Collaboration advances sustainable laboratory workflows. 01 Jun, 2026 Azenta Life Sciences Azenta Life Sciences has entered a collaboration with PulpFixin(R) to help laboratories cut plastic waste while maintaining high standards of performance, traceability, and operational efficiency. The partnership combines Azenta's expertise in sample management and laboratory automation with PulpFixin's AutoRack, a 100% recyclable storage platform designed to support sustainability at scale without requiring major workflow changes, automation revalidation, or disruption to existing sample management processes. Michael Bussmann, Vice President and General Manager of Consumables and Instruments at Azenta, said the company is focused on enabling more environmentally responsible laboratory operations while helping customers progress toward their sustainability targets. "We've already taken steps in this direction, including offering SBS racks made with 90% recycled content, and we continue to look for ways to expand lower-impact options across our portfolio," he said. "By combining PulpFixin's biodegradable rack platform with established FluidX sample management workflows, we're enabling laboratories to reduce reliance on conventional plastic consumables while maintaining compatibility with automation systems, sample integrity, cold-chain performance and operational scalability." Chad Jenkins, CEO of PulpFixin, said the collaboration reflects a shared commitment to improving laboratory sustainability without adding operational burden. "Azenta has consistently demonstrated leadership in helping laboratories modernize operations while addressing evolving expectations around sustainability," he said. "Together, we aim to deliver scalable sample management solutions that reduce the hidden costs associated with plastic waste disposal, recycling logistics and sustainability reporting requirements across laboratory operations." More information online
Azenta, which provides biological sample management and genomic services for pharmaceutical companies, reported Q1 revenues of $144.8 million, up 1% year on year but missing analyst expectations by 2.5%. The company delivered the weakest performance against analyst estimates amongst eight drug development inputs and services stocks tracked. The sector as a group reported satisfactory Q1 results, with revenues beating consensus estimates by 1.6%, though share prices have declined 2.5% on average since earnings. West Pharmaceutical Services, which manufactures packaging and delivery devices for injectable drugs, posted the strongest Q1 performance in the group. Azenta's stock has fallen 23.4% since reporting earnings and currently trades at $17.65.